Wang, Y., Sparano, J. A., Fineberg, S., Stead, L., Sunkara, J., Horwitz, S. B., & McDaid, H. M. (2012). High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer.
Citação norma ChicagoWang, Yihong, Joseph A. Sparano, Susan Fineberg, Lesley Stead, Jaya Sunkara, Susan Band Horwitz, and Hayley M. McDaid. High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer. 2012.
Citação norma MLAWang, Yihong, et al. High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor–Negative Breast Cancer. 2012.